| Literature DB >> 28378007 |
Udai S Sibia1, Kip A Waite1, Maura A Callanan1, Adrian E Park1, Paul J King1, James H MacDonald1.
Abstract
BACKGROUND: Enhanced recovery after surgery protocols for total joint replacements (TJRs) emphasize early discharge, yet the impact on readmissions is not well documented. We evaluate the impact of a one-day length of stay (LOS) discharge protocol on readmissions.Entities:
Keywords: Complications; Enhanced recovery after surgery; Length of stay; Readmissions; Total joint replacement
Year: 2016 PMID: 28378007 PMCID: PMC5365410 DOI: 10.1016/j.artd.2016.05.001
Source DB: PubMed Journal: Arthroplast Today ISSN: 2352-3441
Enhanced recovery after surgery pharmacological protocol.
| Preoperative pain management (single dose within 2 h of incision) |
| Acetaminophen 975 mg PO |
| Lyrica 50 mg PO |
| Protonix 40 mg PO |
| Oxycontin 10 mg PO |
| Scopolamine patch |
| Celebrex 200 mg PO |
| Tranexamic acid (TXA) |
| Total knee replacement |
| Preincision 10 mg/kg, maximum dose 1000 mg |
| 3 h after incision 10 mg/kg, maximum dose 1000 mg |
| Total hip replacement |
| Preincision 10 mg/kg, maximum dose 1000 mg |
| Periarticular injection |
| Morphine 5 mg |
| Toradol 15 mg |
| Ropivicaine 0.5% 30 cc |
| Epinephrine 1/1000 0.3 cc |
| Saline 30 cc |
| Postoperative pain management |
| Total knee replacement |
| Acetaminophen 975 mg PO q 4 as needed |
| Lyrica 50 mg PO bid × 14 d |
| Celebrex 200 mg PO qd × 30 d |
| Oxycodone 5 mg as needed |
| Total hip replacement |
| Acetaminophen 975 mg PO q 4 as needed |
| Oxycodone 5 mg as needed |
| Lyrica 50 mg PO bid × 14 d |
PO, per oral.
Unless contraindicated.
Not given if periarticular injection included Toradol 15 cc.
In select patients with breakthrough pain.
Patient demographics for patients excluded from study.
| Demographics | LOS ≥3 d |
|---|---|
| N | 196 |
| Age (y) | 70.4 |
| Body mass index (kg/m2) | 31.2 |
| Gender | |
| Male | 28.6% |
| Female | 71.4% |
| Comorbidity | |
| Diabetes | 25.0% |
| Hypertension | 74.0% |
| Hyperlipidemia | 57.7% |
| Gastroesophageal reflux disease | 42.3% |
| Coronary artery disease | 12.2% |
| Chronic obstructive pulmonary disease | 11.7% |
| Congestive heart failure | 4.6% |
| Liver cirrhosis | 0.5% |
| Atrial fibrillation | 14.3% |
| Pacemakers | 1.5% |
| Past medical history | |
| History of DVT/PE | 5.6% |
| History of CVA/TIA | 8.2% |
| History of myocardial infarct | 4.1% |
CVA, cerebrovascular accident; DVT, deep vein thrombosis; PE, pulmonary embolism; TIA, transient ischemic attack.
Patient demographics (n = 459).
| Demographics | 1-day LOS | 2-day LOS | |
|---|---|---|---|
| N | 174 | 285 | |
| Age (y) | 61.7 ± 8.6 | 64.8 ± 8.6 | |
| Body mass index (kg/m2) | 30.0 ± 5.8 | 31.4 ± 6.0 | |
| Gender | |||
| Male | 98 (56.3%) | 115 (40.4%) | |
| Female | 76 (43.7%) | 170 (59.6%) | |
| Comorbidity | |||
| Diabetes | 18 (10.3%) | 38 (13.3%) | .343 |
| Hypertension | 96 (55.2%) | 193 (67.7%) | |
| Hyperlipidemia | 87 (50.0%) | 160 (56.1%) | .200 |
| Gastroesophageal reflux disease | 45 (25.9%) | 84 (29.5%) | .404 |
| Coronary artery disease | 12 (6.9%) | 37 (13.0%) | |
| Chronic obstructive pulmonary disease | 6 (3.4%) | 14 (4.9%) | .456 |
| Congestive heart failure | 1 (0.6%) | 3 (1.1%) | .593 |
| Liver cirrhosis | 1 (0.6%) | 2 (0.7%) | .870 |
| Atrial fibrillation | 12 (6.9%) | 27 (9.5%) | .337 |
| Pacemakers | — | 5 (1.8%) | .079 |
| Past medical history | |||
| History of DVT/PE | 4 (2.3%) | 18 (6.3%) | |
| History of CVA/TIA | 5 (2.9%) | 16 (5.6%) | .173 |
| History of myocardial infarct | 4 (2.3%) | 15 (5.3%) | .122 |
The bold signifies P values that meet statistical significance.
CVA, cerebrovascular accident; DVT, deep vein thrombosis; PE, pulmonary embolism; TIA, transient ischemic attack.
Preoperative risk.
| Variable | 1-day LOS (%) | 2-day LOS (%) | |
|---|---|---|---|
| ASA score | .115 | ||
| 1 | 4.0 | 1.8 | |
| 2 | 71.3 | 64.4 | |
| 3 | 23.6 | 31.7 | |
| 4 | 1.1 | 2.1 | |
| Number of comorbidity | .146 | ||
| None | 17.8 | 11.2 | |
| 1 | 28.2 | 25.6 | |
| 2 | 28.7 | 25.3 | |
| 3 | 16.1 | 20.0 | |
| ≥4 | 9.2 | 17.9 |
Perioperative data.
| Variable | 1-day LOS | 2-day LOS | |
|---|---|---|---|
| Anesthesia type | |||
| General | 94 (54.0%) | 196 (68.8%) | |
| Spinal | 80 (46.0%) | 89 (31.2%) | |
| Anterior approach to THA | 73 (83.0%) | 76 (65.0%) | |
| Skin-to-skin operating time (min) | 79.7 ± 14.9 | 85.6 ± 23.5 | |
| Estimated blood loss (mL) | 234.0 ± 158.3 | 264.8 ± 215.5 | .104 |
| Preoperative hematocrit | 41.8 ± 3.4 | 41.4 ± 3.7 | .217 |
| PACU hematocrit | 37.3 ± 3.9 | 36.3 ± 3.8 | .213 |
| POD 1 hematocrit | 33.6 ± 3.9 | 33.3 ± 3.7 | .364 |
| Preoperative hemoglobin | 14.1 ± 1.3 | 13.9 ± 1.3 | .143 |
| POD 1 hemoglobin | 11.0 ± 1.1 | 11.3 ± 1.3 | .303 |
The bold signifies P values that meet statistical significance.
PACU, postoperative acute care unit; THA, total hip arthroplasty.
Postoperative complications.
| Readmissions | 1-day LOS | 2-day LOS | |
|---|---|---|---|
| 7-day readmissions | (0) 0% | (0) 0% | – |
| 30-day readmissions | (0) 0% | 1 (0.4%) | .434 |
| Pulmonary embolism | — | 1 | |
| 90-day readmissions | 2 (1.1%) | 3 (1.1%) | .617 |
| Prosthetic joint infections | — | 1 | |
| Wound infections | 2 | 2 | |
| 30-day all-cause readmissions | 4 (2.3%) | 7 (2.5%) | .591 |